Axsome Therapeutics (AXSM) Enterprise Value (2015 - 2026)

Axsome Therapeutics has disclosed Enterprise Value across 12 years of filings, most recently posting -$305.1 million for Q1 2026.

• Enterprise Value for Q1 2026 came in at -$305.1 million, down 1.4% year-over-year; the trailing twelve-month figure through Mar 2026 was -$305.1 million (down 1.4% YoY), and the FY2025 annual result was -$322.9 million, down 2.4% from the prior year.
• Enterprise Value came in at -$305.1 million for Q1 2026 at Axsome Therapeutics, up from -$322.9 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$73.4 million in Q2 2022 to a low of -$437.1 million in Q2 2023.
• The 5-year median for Enterprise Value is -$315.4 million (2024), against an average of -$289.4 million.
• Across the five-year window, Enterprise Value jumped 48.56% in 2022 and plunged 495.57% in 2023, its largest moves.
• Axsome Therapeutics' Enterprise Value stood at -$200.8 million in 2022, then sank by 92.29% to -$386.2 million in 2023, then increased by 18.34% to -$315.4 million in 2024, then dropped by 2.4% to -$322.9 million in 2025, then grew by 5.52% to -$305.1 million in 2026.
• The last three Enterprise Value figures came in at -$305.1 million (Q1 2026), -$322.9 million (Q4 2025), and -$325.3 million (Q3 2025), per Business Quant data.